PMON01 Alpelisib (PI3-K Inhibitor) Induced Severe Insulin Resistance Complicated by Diabetic Ketoacidosis (DKA) with Rapid Reversal Following Discontinuation: A Case Report

BACKGROUND: Alpelisib is a phosphatidylinositol-3-kinase (PI3K) inhibitor, recently approved for treatment of metastatic breast cancer with PIK3CA mutation. The PI3K is involved in insulin signaling pathway and is responsible for translocation of GLUT-4 transporters in insulin responsive tissues and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lloyd, Jacob, Selk, Karen, Pinkhasova, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Endocrine Disruption
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625240/
http://dx.doi.org/10.1210/jendso/bvac150.913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625240/
http://dx.doi.org/10.1210/jendso/bvac150.913

Ejemplares similares